Shares of IDEXX Laboratories Inc. IDXX inched 0.87% higher to $429.82 Wednesday, on what proved to be an all-around positive ...

Barclays lowered the firm’s price target on Idexx Laboratories (IDXX) to $481 from $570 and keeps an Overweight rating on the shares. The firm sees the softer visit trends continuing based on ...

Idexx Laboratories (IDXX) came out with quarterly earnings of $2.80 per share, beating the Zacks Consensus Estimate of $2.69 per share. This compares to earnings of $2.53 per share a year ago.

For the quarter ended September 2024, Idexx Laboratories (IDXX) reported revenue of $975.54 million, up 6.6% over the same period last year. EPS came in at $2.80, compared to $2.53 in the year-ago ...

Ratings for IDEXX Laboratories (NASDAQ:IDXX) were provided by 4 analysts in the past three months, showcasing a mix of bullish and bearish perspectives. The following table provides a quick ...

Idexx Laboratories Adjusts Guidance As Q3 Revenue Growth Slows, Analyst Notes Fewer Veterinary Visits, Looks Towards Long-Term Growth Idexx Laboratories posted a Q3 EPS of $2.79, beating estimates ...